These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

203 related items for PubMed ID: 16817335

  • 1. Response to cetuximab and gemcitabine-oxaliplatin in an advanced case of intrahepatic cholangiocarcinoma.
    Bralet MP, Bellin MF, Guettier C, Adam R, Paule B.
    Clin Oncol (R Coll Radiol); 2006 Jun; 18(5):426. PubMed ID: 16817335
    [No Abstract] [Full Text] [Related]

  • 2. Gemcitabine and oxaliplatin with or without cetuximab in advanced biliary-tract cancer (BINGO): a randomised, open-label, non-comparative phase 2 trial.
    Malka D, Cervera P, Foulon S, Trarbach T, de la Fouchardière C, Boucher E, Fartoux L, Faivre S, Blanc JF, Viret F, Assenat E, Seufferlein T, Herrmann T, Grenier J, Hammel P, Dollinger M, André T, Hahn P, Heinemann V, Rousseau V, Ducreux M, Pignon JP, Wendum D, Rosmorduc O, Greten TF, BINGO investigators.
    Lancet Oncol; 2014 Jul; 15(8):819-28. PubMed ID: 24852116
    [Abstract] [Full Text] [Related]

  • 3. Panitumumab in combination with gemcitabine and oxaliplatin does not prolong survival in wild-type KRAS advanced biliary tract cancer: A randomized phase 2 trial (Vecti-BIL study).
    Leone F, Marino D, Cereda S, Filippi R, Belli C, Spadi R, Nasti G, Montano M, Amatu A, Aprile G, Cagnazzo C, Fasola G, Siena S, Ciuffreda L, Reni M, Aglietta M.
    Cancer; 2016 Feb 15; 122(4):574-81. PubMed ID: 26540314
    [Abstract] [Full Text] [Related]

  • 4. Hepatic arterial infusion of gemcitabine plus oxaliplatin as second-line treatment for locally advanced intrahepatic cholangiocarcinoma: preliminary experience.
    Ghiringhelli F, Lorgis V, Vincent J, Ladoire S, Guiu B.
    Chemotherapy; 2013 Feb 15; 59(5):354-60. PubMed ID: 24821200
    [Abstract] [Full Text] [Related]

  • 5. Chemotherapy for inoperable advanced or metastatic cholangiocarcinoma: retrospective analysis of 78 cases in a single center over four years.
    Pracht M, Le Roux G, Sulpice L, Mesbah H, Manfredi S, Audrain O, Boudjema K, Raoul JL, Boucher E.
    Chemotherapy; 2012 Feb 15; 58(2):134-41. PubMed ID: 22572213
    [Abstract] [Full Text] [Related]

  • 6. Reversible posterior leukoencephalopathy syndrome associated with concurrent bevacizumab, gemcitabine, and oxaliplatin for cholangiocarcinoma.
    Chang Y, Mbeo G, Littman SJ.
    J Gastrointest Cancer; 2012 Sep 15; 43(3):505-7. PubMed ID: 21556724
    [Abstract] [Full Text] [Related]

  • 7. A Phase I-II dose escalation study of fixed-dose rate gemcitabine, oxaliplatin and capecitabine every two weeks in advanced cholangiocarcinomas.
    Lassen U, Jensen LH, Sorensen M, Rohrberg KS, Ujmajuridze Z, Jakobsen A.
    Acta Oncol; 2011 Apr 15; 50(3):448-54. PubMed ID: 20670085
    [Abstract] [Full Text] [Related]

  • 8. Preliminary experience of cetuximab in the treatment of advanced-stage biliary tract cancer.
    Chang PY, Cheng MF, Lee HS, Hsieh CB, Yao NS.
    Onkologie; 2010 Apr 15; 33(1-2):45-7. PubMed ID: 20164661
    [Abstract] [Full Text] [Related]

  • 9. Gemcitabine and cisplatin combination chemotherapy in intrahepatic cholangiocarcinoma as second-line treatment: report of four cases.
    Lee MA, Woo IS, Kang JH, Hong YS, Lee KS.
    Jpn J Clin Oncol; 2004 Sep 15; 34(9):547-50. PubMed ID: 15466829
    [Abstract] [Full Text] [Related]

  • 10. Intrahepatic Cholangiocarcinoma With Extrahepatic Metastasis and High Tumor Mutation Burden: Case of Complete Pathological Response to Cisplatin/Gemcitabine/Pembrolizumab.
    Robinson MD, Wheatley R, Foster L, Jamdar S, Siriwardena AK, Lamarca A, Hubner R, Valle JW, McNamara MG.
    JCO Precis Oncol; 2024 Apr 15; 8():e2300572. PubMed ID: 38662981
    [No Abstract] [Full Text] [Related]

  • 11. Gemcitabine in combination with EGF-Receptor antibody (Cetuximab) as a treatment of cholangiocarcinoma: a case report.
    Sprinzl MF, Schimanski CC, Moehler M, Schadmand-Fischer S, Galle PR, Kanzler S.
    BMC Cancer; 2006 Jul 17; 6():190. PubMed ID: 16846514
    [Abstract] [Full Text] [Related]

  • 12. Advanced biliary tract carcinomas: a retrospective multicenter analysis of first and second-line chemotherapy.
    Fiteni F, Jary M, Monnien F, Nguyen T, Beohou E, Demarchi M, Dobi E, Fein F, Cleau D, Fratté S, Nerich V, Bonnetain F, Pivot X, Borg C, Kim S.
    BMC Gastroenterol; 2014 Aug 13; 14():143. PubMed ID: 25117717
    [Abstract] [Full Text] [Related]

  • 13. Targeted sequencing and molecular profiling of a papillary and cribriform clear cell intrahepatic cholangiocarcinoma reveals absence of selectable mutations.
    Aldecoa I, Montironi C, Vargas GM, Nunes DA, Miquel R, Cuatrecasas M.
    Gastroenterol Hepatol; 2019 Aug 13; 42(6):374-375. PubMed ID: 30293915
    [No Abstract] [Full Text] [Related]

  • 14. Retrospective analysis of survival benefits of chemotherapy for metastatic or non-resectable intrahepatic cholangiocarcinoma.
    Wiazzane N, Chauffert B, Ghiringhelli F.
    Clin Res Hepatol Gastroenterol; 2013 Dec 13; 37(6):614-8. PubMed ID: 23711827
    [Abstract] [Full Text] [Related]

  • 15. Cetuximab plus gemcitabine-oxaliplatin (GEMOX) in patients with refractory advanced intrahepatic cholangiocarcinomas.
    Paule B, Herelle MO, Rage E, Ducreux M, Adam R, Guettier C, Bralet MP.
    Oncology; 2007 Dec 13; 72(1-2):105-10. PubMed ID: 18025804
    [Abstract] [Full Text] [Related]

  • 16. Combination of gemcitabine and cetuximab in patients with advanced cholangiocarcinoma: a phase II study of the Belgian Group of Digestive Oncology.
    Borbath I, Ceratti A, Verslype C, Demols A, Delaunoit T, Laurent S, Deleporte A, Vergauwe P, Van Maanen A, Sempoux C, Van Cutsem E, Van Laethem JL, Belgian Group of Digestive Oncology.
    Ann Oncol; 2013 Nov 13; 24(11):2824-9. PubMed ID: 23975665
    [Abstract] [Full Text] [Related]

  • 17. Time to move to targeted drugs in biliary tract cancer?
    Louvet C, Tournigand C.
    Onkologie; 2010 Nov 13; 33(1-2):10-1. PubMed ID: 20164655
    [No Abstract] [Full Text] [Related]

  • 18. Phase II study of gemcitabine, oxaliplatin, and cetuximab in advanced pancreatic cancer.
    Merchan JR, Ferrell A, Macintyre J, Ciombor KK, Levi J, Ribeiro A, Sleeman D, Flores A, Lopes G, Rocha-Lima CM.
    Am J Clin Oncol; 2012 Oct 13; 35(5):446-50. PubMed ID: 21552097
    [Abstract] [Full Text] [Related]

  • 19. BINGO: targeted therapy for advanced biliary-tract cancer.
    Valle JW.
    Lancet Oncol; 2014 Jul 13; 15(8):778-80. PubMed ID: 24852117
    [No Abstract] [Full Text] [Related]

  • 20. Delayed response to maintenance therapy after first-line chemotherapy in metastatic intrahepatic cholangiocarcinoma: a case report.
    Marciano R, Servetto A, Bianco C, Bianco R.
    J Med Case Rep; 2017 Sep 26; 11(1):273. PubMed ID: 28946921
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.